Treatment Updates in Myelofibrosis from ASCO 2023

 

Dana-Farber Cancer Institute
J

Practical Considerations for the Management of Myelofibrosis: JAK Inhibitors and Beyond

By Dana-Farber Cancer Institute FEATURING Jacqueline Garcia
By Dana-Farber Cancer Institute FEATURING Jacqueline Garcia
161 views
May 8, 2023
0 Comments
Login to view comments. Click here to Login
Treatment Updates in Myelofibrosis from ASCO 2023
11:34
Karen Carlson

Learnings From the FREEDOM Trials: Real-World Experience With Fedrat…

12:20
Ruben Mesa

The Updated NCCN Guidelines for the Management of Myelofibrosis

03:42
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "BELLWAVE-003 - A Phase 2 Dose Escalation,…

Feat. G. Perini
10:46
Icahn School of Medicine at Mount Sinai

Overview of JAKARTA & JAKARTA2 Trials: Impact of Fedratinib on S…

Feat. J. Waksal
16:21
Ciro Rinaldi

Challenges in Treating Myelofibrosis

29:15
William Hogan

Contemporary Management of Splenomegaly in Myelofibrosis

08:48
Dana-Farber Cancer Institute

Practical Considerations for the Management of Myelofibrosis: JAK In…

Feat. J. Garcia
17:49
Kristen Pettit

Latest Advances in Myelofibrosis Treatment

05:06
ASH 2021 Conference Coverage on VuMedi

Positioning Fedratinib in the Treatment Strategy of Myelofibrosis

Feat. F. Passamonti
22:30
Indy Hematology Review

Targets and Treatments of MPNs in 2023

Feat. R. Mesa
31:43
Indy Hematology Review

Myelofibrosis: Chronic and Blast Phase - 2023 Algorithms for Risk St…

Feat. A. Tefferi
27:18
UChicago Medicine

Best of ASH: Myelofibrosis

Feat. S. Kosuri